FM Protocols
Peptides for Inflammation: What Functional Medicine Practitioners Need to Know
The four peptides FM practitioners most often discuss for inflammation: proposed mechanisms, the evidence behind each, and how they fit with foundational care.
The peptides FM practitioners most often discuss for inflammation are BPC 157, thymosin beta-4, GHK-Cu and KPV. Most of the evidence for them comes from animal and cell studies, with very few human trials, so they sit as possible adjuncts to foundational care, and their use is an individualized prescribing decision.
Why Peptides Come Up for Inflammation
FM practitioners already have a broad anti-inflammatory toolkit, including diet, sleep, stress and gut-focused care. Peptides tend to come up for patients whose symptoms persist after that groundwork. Their proposed actions on growth factors, cytokine signaling and tissue repair come mostly from preclinical research.
The Four Peptides Most Often Discussed
BPC 157
Proposed mechanism: A 2025 systematic review describes preclinical studies in which BPC 157 reduced inflammatory cytokines and improved healing of muscle, tendon, ligament and bone injuries.
Where it comes up: gut inflammation and tendon or soft-tissue injury.
Evidence: Of the 36 studies in that systematic review, 35 were preclinical and 1 was clinical, and no clinical safety data were found.
Thymosin beta-4 (TB4)
Proposed mechanism: A review describes TB4 limiting inflammation through autophagy in animal studies.
Where it comes up: chronic inflammatory states and tissue repair.
Evidence: A small phase 2 randomized trial of TB4 eye drops improved signs and symptoms of severe dry eye. Evidence for systemic inflammatory conditions is preclinical, according to the same autophagy review.
GHK-Cu (copper peptide)
Proposed mechanism: Gene data suggest GHK regulates multiple biochemical pathways tied to tissue repair and anti-inflammatory actions.
Where it comes up: tissue repair, wound healing and skin.
Evidence: A review describes wound-healing effects in rats, mice, pigs and dogs, and cosmetic skin findings in people. Systemic anti-inflammatory use in humans has not been studied in trials that review cites.
KPV (Lys-Pro-Val)
Proposed mechanism: KPV is a fragment of alpha-MSH, and in two mouse models of inflammatory bowel disease it reduced inflammation.
Where it comes up: gut inflammation.
Evidence: The KPV colitis study is animal research, and we found no human trials.
How Peptides Fit With Foundational Care
Foundational work on diet, gut health, sleep and stress remains the base of care. Peptides, when used, are adjuncts to that base. Agent selection, route, dose, duration and combinations are individualized prescribing decisions for the treating clinician, and a 2025 systematic review notes that BPC 157 lacks FDA approval.
Monitoring
Clinicians typically follow symptoms and patient-reported outcomes along with the inflammatory markers they already use. Which markers to track, and when, is a decision for the treating clinician.
The Evidence Base
Most peptide inflammation research is in animal models, and human clinical trials are sparse:
- BPC 157: 35 of 36 studies preclinical
- TB4: a small phase 2 dry eye trial
- GHK-Cu: animal wound healing and cosmetic data
- KPV: mouse colitis models
Practitioners using peptides should be clear with patients about how limited the human evidence is.
FAQ
Can peptides replace NSAIDs?
There are no head-to-head human trials comparing them. For acute inflammation, standard care applies.
Do anti-inflammatory peptides suppress the immune system?
Preclinical data suggest they modulate inflammatory signaling. Human data on immune effects are limited.
Can multiple peptides be combined?
Combinations have not been studied in human trials, so this is a prescribing decision for the treating clinician.
Are these peptides FDA approved?
A 2025 systematic review notes that BPC 157 lacks FDA approval and is banned in professional sports. Regulatory status varies by peptide.
For the broader framework, see Peptide Therapy Protocols: A Functional Medicine Practitioner's Guide. For BPC 157 specifically, see BPC 157 Healing Protocol and BPC 157 for Gut Healing.
Ready to document complex cases efficiently? HANS is a clinical AI copilot that runs beside your EMR, with patient timelines for inflammatory marker trends. See HANS pricing and features.